Peripheral Arterial Disease Clinical Trial
— ePADOfficial title:
A Randomized, Open-Label, Parallel-Group, Multi-Center Study Of Adding Edoxaban Or Clopidogrel To Aspirin To Maintain Patency In Subjects With Peripheral Arterial Disease Following Femoropopliteal Endovascular Intervention
Verified date | January 2018 |
Source | Daiichi Sankyo, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is a randomized, open-label, blinded endpoint, parallel-group, active-control, multi-center, proof-of-concept study in subjects with Peripheral Arterial Disease (PAD), designed to assess the safety and potential efficacy of adding edoxaban to aspirin following femoropopliteal endovascular intervention, with or without stent placement, relative to current treatment practice with clopidogrel and aspirin.
Status | Completed |
Enrollment | 203 |
Est. completion date | December 3, 2014 |
Est. primary completion date | December 3, 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Male or female subjects older than the minimum legal adult age (country specific); - Rutherford stages 2-5 provided there are no ulcerations on the heel and/or exposed tendon and/or bone; - Superficial femoral above knee-popliteal ( 3 cm proximal to the medial femoral condyle) lesion and = 50% stenosis or occlusion; - At least one run-off vessel to the foot with or without additional endovascular intervention; - Successful intervention, defined as angiographic confirmation of = 30% residual stenosis and absence of flow limiting dissection; - Adequate hemostasis at the vascular access site within 24 hours of intervention; - A subject is also eligible if they have undergone additional successful endovascular intervention(s) during the index intervention; - Able to provide signed informed consent. Exclusion Criteria: - Calculated Creatinine Clearance < 30 ml/min; - Femoral or popliteal aneurysm; - Adjunctive use of thrombolytics; - Any extravasation or distal embolization not successfully treated; - Uncontrolled hypertension as judged by the investigator (e.g., systolic blood pressure > 170 mmHg or diastolic blood pressure > 100 mmHg despite antihypertensives); - Aspirin intolerance; - Clopidogrel intolerance; - Contraindication for anticoagulants or antiplatelets and any other contraindication listed in the local labeling of aspirin and/or clopidogrel; - Active bleeding or known high risk for bleeding or history of intracranial, or spontaneous intraocular, spinal retroperitoneal or intra-articular bleeding; overt gastrointestinal (GI) bleeding or active ulcer within the previous year; - Subjects receiving dual antiplatelet or anticoagulant therapy at the time of randomization; subjects receiving pre-interventional loading dose of clopidogrel or other P2Y12 receptor antagonists; - Treatment with cilostazol within 24 hours of randomization; - Subjects receiving prohibited concomitant medications [fibrinolytics, chronic use of non steroidal anti-inflammatory drugs (NSAIDS) > 4 days per week, and oral or parenteral non-aspirin NSAIDs and strong P-gp inhibitors]; - Prior stroke or myocardial infarction (MI) or acute coronary syndrome within 3 months; - Chronic liver disease [alanine transaminase (ALT) and/or aspartate transaminase (AST) = 2 × upper limit of normal; total bilirubin (TBL) = 1.5 × upper limit of normal]; however, subjects whose elevated TBL is due to known Gilbert?s syndrome may be included in the study; - Prior history of a positive test for Hepatitis B antigen or Hepatitis C antibody; - Subjects who received any investigational drug or device within 30 days prior to randomization, or plan to receive such investigational therapy during the study period; - Subjects previously randomized to an edoxaban (DU-176b) study; - Women of childbearing potential without proper contraceptive measures (i.e. a method of contraception with a failure rate < 1 % during the course of the study including the observational period) and women who are pregnant or breast feeding; - Subjects with the following diagnoses or situations: Active malignancy except for adequately treated non-melanoma skin cancer or other non-invasive or in-situ neoplasm (e.g., cervical cancer in situ); Concurrent treatment with cancer therapy (drugs, radiation, and/or surgery); Other significant active concurrent medical illness or infection; Life expectancy < 12 months; - Subjects who are unlikely to comply with the protocol (e.g., uncooperative attitude, inability to return for subsequent visits, and/or otherwise considered by the Investigator to be unlikely to complete the study); - Subjects with any condition that, in the opinion of the Investigator, would place the subject at increased risk of harm if he/she participated in the study; - History of heparin-induced thrombocytopenia |
Country | Name | City | State |
---|---|---|---|
Belgium | Edgem | Edegem |
Lead Sponsor | Collaborator |
---|---|
Daiichi Sankyo, Inc. | UMC Utrecht |
United States, Austria, Belgium, Germany, Israel, Netherlands, Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants With Clinically Relevant Bleeding During Treatment | Percentage of participants with clinically relevant bleeding, defined as major bleeding or clinical relevant non-major bleeding, in the on-treatment period based on International Society of Thrombosis and Haemostasis (ISTH) | at 3 months | |
Primary | Percentage of Participants With First Re-stenosis / Re-occlusion | Percentage of participants with re-stenosis/re-occlusion during treatment within 6 months - only the first occurrence of re-stenosis / re-occlusion was counted for each participant | within 6 months | |
Secondary | Percentage of Participants With Major, Clinically Relevant Non-major (CRNM), and Minor Bleeding During Treatment | The percentage of participants with major, clinically relevant non-major, and minor bleeding occurring during treatment, within 3 months | within 3 months | |
Secondary | Safety Assessments | Number of participants with serious adverse events (SAEs) within 6 months Note: Based on changes to the database structure, clinically significant changes in physical or laboratory parameters are recorded as adverse events (AEs). Details of non-serious adverse events are reported at the 5% reporting threshold in the AE module, as is all-cause mortality. |
within 6 months | |
Secondary | Number of Adjudicated Major Adverse Cardiovascular Events During the Overall Study Period | Number of Adjudicated Major Adverse Cardiovascular Events (MACE) which is a composite of non-fatal myocardial infarction (MI), non-fatal stroke and cardiovascular death | within 6 months | |
Secondary | Number of Participants With Amputations | Number of participants with amputations within 6 months | within 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Active, not recruiting |
NCT04677725 -
NEtwork to Control ATherothrombosis (NEAT Registry)
|
||
Recruiting |
NCT05961943 -
RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients
|
N/A | |
Recruiting |
NCT06047002 -
Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
|
||
Completed |
NCT03185052 -
Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach
|
N/A | |
Recruiting |
NCT05992896 -
A Study of Loco-Regional Liposomal Bupivacaine Injection
|
Phase 4 | |
Completed |
NCT04635501 -
AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial
|
N/A | |
Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
Withdrawn |
NCT03994185 -
The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease
|
N/A | |
Withdrawn |
NCT03538392 -
Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
|
||
Recruiting |
NCT02915796 -
Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty
|
Phase 1 | |
Active, not recruiting |
NCT02900924 -
Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
|
||
Completed |
NCT02901847 -
To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
|
N/A | |
Not yet recruiting |
NCT02387450 -
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
|
Phase 2/Phase 3 | |
Withdrawn |
NCT02126540 -
Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries
|
N/A | |
Not yet recruiting |
NCT02455726 -
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
|
N/A | |
Completed |
NCT02022423 -
Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease
|
N/A |